Viewing Study NCT07296705


Ignite Creation Date: 2025-12-25 @ 3:27 AM
Ignite Modification Date: 2026-01-16 @ 4:00 PM
Study NCT ID: NCT07296705
Status: RECRUITING
Last Update Posted: 2025-12-22
First Post: 2025-09-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Sponsor: Fujian Medical University Union Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module